Proposed Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N)

July 5, 2013
The federal Centers for Medicare & Medicaid Services (CMS) reviewed evidence about the effectiveness of positron emission tomography (PET) and Eli Lilly’s Amyvid amyloid-beta imaging agent for Medicare beneficiaries with dementia. CMS said that the evidence is insufficient to conclude that Amyvid-augmented PET imaging improves health outcomes for Medicare beneficiaries with dementia or neurodegenerative disease. CMS did say that there was sufficient evidence that the PET-Amyvid imaging could be promising in two scenarios: to exclude Alzheimer’s disease to resolve clinically difficult differential diagnoses or to select participants for clinical trials seeking better . . .